Mineralys Therapeutics (MLYS) Stock: Buy, Sell, or Hold?
MLYS - Mineralys Therapeutics, Inc. Common Stock
$23.37
0.99 (4.42%)
▲
5d:
-1.1%
30d:
-20.24%
90d:
-15.3%
HOLD
LOW Confidence
Analysis Updated: Oct 9, 2026 12:00 AM ET
Earnings: Nov 09, 2026
27d
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Oct 7, 2026 at $22.33 · last confirmed Oct 9, 2026
Strength: 8.1/10
Get Alerted When MLYS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: MLYS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: MLYS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: MLYS is currently trading at $23.37, which is considered oversold relative to its 30-day fair value range of $24.12 to $29.21.
Technical Outlook: Technically, MLYS is showing sideways momentum. Immediate support is located at $21.46, while resistance sits at $25.95. The stock is showing strong short-term momentum, up 4.4% recently.
Market Sentiment: MLYS scores 75/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $48.50 (+107.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, MLYS is showing sideways momentum. Immediate support is located at $21.46, while resistance sits at $25.95. The stock is showing strong short-term momentum, up 4.4% recently.
Market Sentiment: MLYS scores 75/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $48.50 (+107.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$24.12 -
$29.21
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
100.0%
Protect Your Profits
Holding MLYS? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.4%)
- BULLISH: Trading 107.5% below Wall St target ($48.50)
- CAUTION: Bottoming setup, but lagging the sector by 23% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$24.12 -
$29.21
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$21.46
Resistance Level
$25.95
Current Trend
Sideways
Technical data as of
Oct 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-9.35
Wall Street Target
$48.50
(+107.5%)
Share & Embed Analysis
Last updated: October 12, 2026 4:23 AM ET
Data refreshes hourly during market hours. Next update: 5:23 AM
Data refreshes hourly during market hours. Next update: 5:23 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MLYS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
David Malcom Rodman
SELL
416 shares
2026-04-17
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
20 analysts |
$36 | 53 HOLD |
|
SRRK
Scholar Rock Holding Corp |
STRONG BUY
18 analysts |
$70 | 50 HOLD |
|
WVE
Wave Life Sciences Ltd |
STRONG BUY
19 analysts |
$18 | 50 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
14 analysts |
$146 | 63 BUY |
|
ZYME
Zymeworks Inc. Common St… |
STRONG BUY
14 analysts |
$41 | 58 HOLD |
Advanced MLYS Option Strategies
Professional options setups generated by AI based on today's MLYS price and gamma walls.
